PRECIGEN
Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
PRECIGEN
Industry:
Biotechnology Life Science Medical Therapeutics
Founded:
1998-01-01
Address:
Germantown, Maryland, United States
Country:
United States
Website Url:
http://www.precigen.com
Total Employee:
101+
Status:
Active
Contact:
15409610734
Email Addresses:
[email protected]
Total Funding:
630.8 M USD
Technology used in webpage:
Domain Not Resolving DNSSEC Microsoft Apple Whitelist ASP.NET 2.0 Klarna
Similar Organizations
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-01-24 | GenVec | GenVec acquired by Precigen | N/A |
| 2016-02-25 | EnviroFlight | EnviroFlight acquired by Precigen | N/A |
| 2015-08-10 | Oxitec | Oxitec acquired by Precigen | 160 M USD |
| 2015-02-13 | ActoGeniX | ActoGeniX acquired by Precigen | 60 M USD |
| 2013-12-20 | Medistem | Medistem acquired by Precigen | N/A |
| 2011-10-24 | Immunologix | Immunologix acquired by Precigen | N/A |
| 2011-02-02 | Agarigen, Inc | Agarigen, Inc acquired by Precigen | N/A |
Investors List
Randal J. Kirk
Randal J. Kirk investment in Series F - Precigen
Third Security
Third Security investment in Series F - Precigen
Randal J. Kirk
Randal J. Kirk investment in Series E - Precigen
NewVa Capital Partners
NewVa Capital Partners investment in Series E - Precigen
Third Security
Third Security investment in Series E - Precigen
Third Security
Third Security investment in Series C - Precigen
NewVa Capital Partners
NewVa Capital Partners investment in Venture Round - Precigen
Third Security
Third Security investment in Series B - Precigen
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2014-12-02 | Histogenics | Precigen investment in Post-IPO Equity - Histogenics | 70 M USD |
Key Employee Changes
Official Site Inspections
http://www.precigen.com Semrush global rank: 4.42 M Semrush visits lastest month: 2.35 K
- Host name: 174.60.185.35.bc.googleusercontent.com
- IP address: 35.185.60.174
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Precigen"
About - Precigen
Precigen’s mission is to discover, develop and commercialize next generation gene and cell therapies focused in immuno-oncology, autoimmune disorders, and infectious diseases. Our …See details»
Precigen - Wikipedia
Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the functi…See details»
Precigen - Crunchbase Company Profile & Funding
Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a …See details»
Precigen - LinkedIn
Precigen: Advancing Medicine with Precision™ Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of …See details»
Innovating highly differentiated gene and cell therapies targeting ...
Precigen is a clinical stage biopharmaceutical company based in the United States focused on developing transformative gene and cell therapies that are differentiated ...See details»
Precigen, Inc. - AnnualReports.com
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target …See details»
Precigen Announces Departure of Chief Financial Officer
GERMANTOWN, Md., March 30, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the …See details»
Precigen Company Profile - Office Locations, Competitors ... - Craft
Oct 25, 2024 Precigen has 1 employees across 3 locations and $26.91 m in annual revenue in FY 2022. See insights on Precigen including office locations, competitors, revenue, financials, …See details»
Governance - Precigen
10 rows Governance Press & Events Stock Financials Governance Resources Governance Documents Committee Charters IRS Form 8937 Related to Name Change from Intrexon to …See details»
Precigen Reports Third Quarter 2023 Financial Results and …
GERMANTOWN, Md., Nov. 9, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell …See details»
Precigen Reports First Quarter 2022 Financial Results and Business ...
May 9, 2022 Contract research organization costs and lab supplies increased $1.6 million with the advancement of the Company's clinical and preclinical programs. Selling, general and …See details»
Precigen Highlights Pipeline Updates to be Presented at the 42nd …
Jan 8, 2024 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today …See details»
Precigen Reports Fourth Quarter and Full Year 2021 Financial Results
GERMANTOWN, Md., March 1, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell …See details»
Precigen Reports Third Quarter 2022 Financial Results and …
GERMANTOWN, Md., Nov. 9, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell …See details»
Precigen Reports Fourth Quarter and Full Year 2022 Financial …
Mar 6, 2023 This decrease was primarily driven by a reduction in contract research organization costs of $0.9 million, primarily due to timing differences, the completion of the 1b /2a clinical …See details»
Pipeline - Precigen
PRECIGEN pipeline. Discovery by Design. Our pipeline includes several programs leveraging our technologies in core therapeutic areas of immuno-oncology, autoimmune disorders, and …See details»
Investors - Precigen
Advancing Medicine with Precision® Press & Events Stock Financials Governance Resources Nasdaq: PGEN Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage …See details»
Careers - Precigen
Precigen’s Medical Transparency in Coverage This link leads to the machine-readable files that are made available in response to the federal Transparency in Coverage Rule and includes …See details»
Precigen Reports First Quarter 2020 Financial Results
May 6, 2020 Salaries, benefits and other personnel costs decreased $2.1 million, and contract research organization costs and lab supplies decreased $5.1 million as Precigen narrowed its …See details»